The reiteration of a Neutral rating and maintenance of the price target suggests that Wedbush sees no new catalysts or changes in fundamentals that would alter the investment thesis for AnaptysBio in the short term. This is likely to have a neutral impact on the stock as it does not change the market's existing perception of the company's value.